BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35542888)

  • 1. Synthesis and biological evaluation of geldanamycin-ferulic acid conjugate as a potent Hsp90 inhibitor.
    Li Z; Jia L; Tang H; Shen Y; Shen C
    RSC Adv; 2019 Dec; 9(72):42509-42515. PubMed ID: 35542888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo Evaluation of 17-phenylpropylamine/phenoxyethylamine- 17-demethoxygeldanamycins as Potent Hsp90 Inhibitors.
    Li Z; Jia L; Xu H; Lu C; Shena Y
    Med Chem; 2015; 11(5):482-8. PubMed ID: 25537129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LZY3016, a novel geldanamycin derivative, inhibits tumor growth in an MDA-MB-231 xenograft model.
    Li Z; Jia L; Tang H; Shen Y; Shen C
    RSC Adv; 2023 May; 13(20):13586-13591. PubMed ID: 37152572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
    Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
    Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
    Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy.
    McCombs JR; Chang HP; Shah DK; Owen SC
    Int J Pharm; 2021 Dec; 610():121272. PubMed ID: 34763035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
    Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
    Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.
    Liang C; Hao H; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2016 Oct; 121():272-282. PubMed ID: 27266997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy.
    Mahanta S; Pilla S; Paul S
    Med Hypotheses; 2013 Sep; 81(3):463-9. PubMed ID: 23860250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
    Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.
    Wu WC; Wu MH; Chang YC; Hsieh MC; Wu HJ; Cheng KC; Lai YH; Kao YH
    Exp Eye Res; 2010 Aug; 91(2):211-9. PubMed ID: 20493187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.